106 related articles for article (PubMed ID: 8726540)
1. Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease.
Bordet R; Broly F; Destée A; Libersa C; Lafitte JJ
Clin Neuropharmacol; 1996 Jun; 19(3):213-21. PubMed ID: 8726540
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body disease.
Bordet R; Broly F; Destee A; Libersa C
Clin Neuropharmacol; 1994 Oct; 17(5):484-8. PubMed ID: 9316701
[TBL] [Abstract][Full Text] [Related]
3. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families.
Lucotte G; Turpin JC; Gérard N; Panserat S; Krishnamoorthy R
Am J Med Genet; 1996 Jul; 67(4):361-5. PubMed ID: 8837703
[TBL] [Abstract][Full Text] [Related]
4. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
5. [Cytochrome P450*2D6 gene polymorphism in Chinese population].
Tao E; Liu Z; Chen B; Pan X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1998 Feb; 15(1):34-7. PubMed ID: 9456373
[TBL] [Abstract][Full Text] [Related]
6. A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease.
Tsuneoka Y; Matsuo Y; Iwahashi K; Takeuchi H; Ichikawa Y
J Biochem; 1993 Aug; 114(2):263-6. PubMed ID: 7903297
[TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease.
Tsuneoka Y; Matsuo Y; Ichikawa Y; Watanabe Y
Metabolism; 1998 Jan; 47(1):94-6. PubMed ID: 9440484
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism of CYP2D6 in the Japanese population.
Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
[TBL] [Abstract][Full Text] [Related]
9. [Association between the debrisoquine hydroxylase gene polymorphism and the genetic susceptibility of Parkinson's disease].
Tao E; Liu Z; Chen B; Pan X; Shao M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1998 Oct; 15(5):281-3. PubMed ID: 9758873
[TBL] [Abstract][Full Text] [Related]
10. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism.
Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I
Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480
[TBL] [Abstract][Full Text] [Related]
11. Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease.
Pang CP; Zhang J; Woo J; Chan D; Law LK; Tong SF; Kwok T; Kay R
Mov Disord; 1998 May; 13(3):529-32. PubMed ID: 9613747
[TBL] [Abstract][Full Text] [Related]
12. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.
Yokoi T; Kosaka Y; Chida M; Chiba K; Nakamura H; Ishizaki T; Kinoshita M; Sato K; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1996 Oct; 6(5):395-401. PubMed ID: 8946471
[TBL] [Abstract][Full Text] [Related]
13. Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson's disease.
Santt O; Baranova H; Albuisson E; Bignon YJ; Lucotte G
Eur J Neurol; 2004 Apr; 11(4):247-51. PubMed ID: 15061826
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquine hydroxylase and Parkinson's disease.
Kondo I; Kanazawa I
Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism and Parkinson's disease in Taiwan: study of debrisoquine 4-hydroxylase (CYP2D6).
Lo HS; Chen CH; Hogan EL; Kao KP; Wang V; Yan SH
J Neurol Sci; 1998 Jun; 158(1):38-42. PubMed ID: 9667775
[TBL] [Abstract][Full Text] [Related]
16. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
17. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
Ur Rasheed MS; Mishra AK; Singh MP
Neurochem Res; 2017 Dec; 42(12):3353-3361. PubMed ID: 28871472
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
20. Mutant debrisoquine hydroxylation genes in Parkinson's disease.
Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR
Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
